Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Change in Receivables (2020 - 2025)

Strata Critical Medical (SRTA) has disclosed Change in Receivables for 6 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 233.3% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2025, up 1105.81% year-over-year, with the annual reading at $12.0 million for FY2025, 1105.81% up from the prior year.
  • Change in Receivables for Q4 2025 was $3.5 million at Strata Critical Medical, up from $1.8 million in the prior quarter.
  • The five-year high for Change in Receivables was $6.3 million in Q2 2025, with the low at -$3.4 million in Q3 2024.
  • Average Change in Receivables over 5 years is $1.6 million, with a median of $886000.0 recorded in 2022.
  • The sharpest move saw Change in Receivables soared 2369.46% in 2022, then plummeted 1990.4% in 2024.
  • Over 5 years, Change in Receivables stood at $1.8 million in 2021, then tumbled by 50.31% to $886000.0 in 2022, then crashed by 114.11% to -$125000.0 in 2023, then tumbled by 1990.4% to -$2.6 million in 2024, then surged by 233.3% to $3.5 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $3.5 million, $1.8 million, and $6.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.